Last edition
News about "NSCLC treatment"
J&J's RYBREVANT Plus Chemotherapy Delivers Nearly 3-Year Survival in EGFR Exon 20 NSCLC
J&J’s RYBREVANT (amivantamab) plus chemotherapy delivers a median Overall Survival of 34.3 months in EGFR exon 20 insertion mutation-positive Non-Small Cell Lung Cancer (NSCLC).
NSCLC Treatment | 14/09/2026 | By News Bureau | 100
Xcovery Partners with EVERSANA to Launch Ensacove in US
Xcovery Holdings Inc. partners with EVERSANA to commercialize Ensacove in the U.S., leveraging end-to-end services including market access, medical and commercial support to expand lung cancer treatment availability.
NSCLC Treatment | 28/04/2026 | By News Bureau | 211
MHRA Approves Bayer's Sevabertinib for HER2-Mutated Advanced Lung Cancer
Sevabertinib, a targeted therapy for HER2-mutated lung cancer, has been approved by the UK regulator to expand treatment options for advanced-stage patients.
NSCLC Treatment | 04/04/2026 | By News Bureau | 197
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy